Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study | Zendy

Charles M. Rudin | Zendy; Mark M. Awad | Zendy; Alejandro Navarro | Zendy; Maya Gottfried | Zendy; Solange Peters | Zendy; Tibor Csöszi | Zendy; Parneet Cheema | Zendy; Delvys RodríguezAbreu | Zendy; Mirjana Wollner | Zendy; James ChihHsin Yang | Zendy; Julien Mazières | Zendy; F. Orlandi | Zendy; Alexander Luft | Zendy; Mahmut Gümüş | Zendy; Terufumi Kato | Zendy; Gregory P. Kalemkerian | Zendy; Yiwen Luo | Zendy; Victoria Ebiana | Zendy; M. Catherine Pietanza | Zendy; Hye Ryun Kim | Zendy

Open Access

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Author(s) -

Charles M. Rudin,

Mark M. Awad,

Alejandro Navarro,

Maya Gottfried,

Solange Peters,

Tibor Csöszi,

Parneet Cheema,

Delvys RodríguezAbreu,

Mirjana Wollner,

James ChihHsin Yang,

Julien Mazières,

F. Orlandi,

Alexander Luft,

Mahmut Gümüş,

Terufumi Kato,

Gregory P. Kalemkerian,

Yiwen Luo,

Victoria Ebiana,

M. Catherine Pietanza,

Hye Ryun Kim

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.00793

Subject(s) - pembrolizumab , medicine , placebo , lung cancer , hazard ratio , clinical endpoint , etoposide , population , gastroenterology , progression free survival , oncology , randomized controlled trial , surgery , confidence interval , cancer , chemotherapy , immunotherapy , pathology , alternative medicine , environmental health

Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage (ES) SCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research